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Introduction
Driving under the inﬂuence of substances (DUI) other than
alcohol has been the subject of increasing interest over the past few
decades (Schulze et al., 2012). As with alcohol, research has shown
that drug intake increases the risk of road trafﬁc accidents (Elvik,
2013; Schulze et al., 2012; Verstraete & Legrand, 2014). Interven-
tion in this area is a priority. A key factor for deterring DUI is to
convince drug-using drivers that the risk of detection is high
(Jones, Donnelly, Swift, & Weatherburn, 2006; Watling, Palk,
Freeman, & Davey, 2010) thus, adequate law enforcement, and the
continuity of roadside testing for drug use among drivers, play an
important role (Shepherd, 2001; Watson & Freeman, 2007).
For the European Project DRUID (Driving under the Inﬂuence
of Drugs, Alcohol and Medicines; http://www.druid-project.eu),
roadside surveys were conducted in 13 European countries and
results showed large differences in the prevalence of alcohol and
drug intake by country (Schulze et al., 2012). The highest
prevalence was found in Southern Europe (Italy, Spain and
Portugal). In Spain, avoiding driving after alcohol or drug use
has been recognized as crucial to improving road safety. Five
years after the DRUID project, a new roadside survey was
conducted following a similar methodology in order to study
whether the use of alcohol and drugs among Spanish drivers had
changed.
Methods
The survey target population was motor vehicle drivers,
excluding bikers and drivers of vehicles over 3500 kg, on Spanish
public roads. The prevalence of drivers under the inﬂuence of
substances was compared using results of two cross-sectional
studies conducted in 2008–9 (time 1) and 2013 (time 2) in separate
representative samples of the general population of Spanish
drivers. Drivers were selected at random from the total population
of drivers using a sampling scheme stratiﬁed by country areas,
time period, population size, and road type, following DRUID
criteria as previously described (Go´mez-Talego´n et al., 2012). A
total of 128 police roadside checkpoints were selected. The data
were weighted according to the trafﬁc intensity at each
checkpoint. The study included a total sample size of 6234 drivers:
3302 at time 1 (with samples taken between September 26th,
2008 and August 24th, 2009) and 2932 at time 2 (with samples
taken at two different time periods, May and November). In Spain,
roadside police controls are legally regulated. Alcohol test and on-
road saliva analysis are both mandatory. Refusal to be tested has
the same penalty as a positive test (1000 euros ﬁne and a loss of
6 driver points). Therefore, no drivers refused to participate.
However, in 20 cases in 2008–9, the driver was either unable to
produce enough saliva to carry out the drug test or there was an
error with the device being used. In 2013, ﬁve drivers were unable
to produce enough saliva to test.
Substances analyzed and toxicological aspects
Roadside police controls used mandatory alcohol tests and on-
road saliva analysis. Breath tests for alcohol were carried out using
the Dra¨ger Alcotest1 6810 device and an on-site oral ﬂuid drugs
test (screening), with the Dra¨ger Drug Test1 5000 analyzer
(Dra¨ger, 2015). Identical (having the same technical speciﬁcations
and cut offs) (Go´mez-Talego´n et al., 2012) test kits were used at
time 1 and 2 for multiple and simultaneous detection of
amphetamines, methamphetamines, opiates, cocaine, cannabis
and benzodiazepines. The oral ﬂuid samples used in the
conﬁrmatory analysis were collected with the StatSureTM Sali-
vaSamplerTM for the ﬁrst group of samples (time 1) and with
QuantisalTM in the second (time 2). The Statsure and Quantisal
devices contained 1.0 and 3 ml of buffer respectively. The collected
volumes of oral ﬂuid were determined for each sample by weight.
Drug concentrations in undiluted oral ﬂuid were calculated by
considering oral ﬂuid density as 1 g/ml (Concheiro, de Castro,
Quintela, Cruz, & Lo´pez-Rivadulla, 2008). The analyses were
carried out at both times by the University of Santiago de
Compostela. The storage and cooling process, transportation and
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subsequent analysis in the laboratory has previously been
described (Go´mez-Talego´n et al., 2012). At time 2, only the
samples of drivers testing positive in the screening were later
analyzed in the laboratory. Consequently, the variables at time
1 were recodiﬁed following the same criteria. Samples were
categorized as ‘‘negative’’ when the drivers’ results were negative
in the screening test. For both studies, a ﬁnal positive result was
deﬁned as a concentration higher than the cut-offs established in
the DRUID project for any of the analyzed substances in the
laboratory, or having a breath alcohol concentration of >0.05 mg/L
(Table 1).
The positives in the screening were deﬁned in terms of four
dichotomous variables (yes/no): ‘‘only alcohol’’, ‘‘only drugs’’,
‘‘alcohol and drugs’’ and ‘‘any substance’’. Regarding conﬁrmatory
analysis, two variables were considered: ‘‘any substance’’ (yes/no)
and a categorical variable with nine groups: negative/THC positive/
cocaine positive/amphetamine positive/opiate positive/alcohol
positive/benzodiazepine positive/positive for a combination of
drugs/alcohol + drug positive.
Statistical analyses
Absolute and relative frequencies with 95% conﬁdence intervals
(CIs) are shown. The two-tailed two-proportion z-test was used to
determine whether the difference between two proportions was
signiﬁcant. Statistical analyses were carried out with the Statistical
Package for the Social Sciences (SPSS, v19). The level of signiﬁcance
was set at p  0.05.
Results
At time 2, 12.07% of the on-road trafﬁc controls tested positive
for alcohol and/or drugs in the screening test, which shows a
decrease of 4.27 points compared with time 1 (16.34% Table 2). At
time 2, cases testing positive for both alcohol and drugs were also
less frequently observed. Compared to time 1, there was a decrease
in the prevalence of cases testing positive for alcohol (and negative
for drugs) as well as cases testing positive for drugs (and negative
for alcohol).
At time 2, 9.34% of cases were conﬁrmed to have some
substance present compared to 14.05% at time 1, indicating a
decrease of 4.71 points (Table 2). A decrease was observed in the
prevalence of cases testing positive for alcohol and drugs from
2008–9 to 2013. Upon analyzing the different combinations of
substances, differences were observed in the cases testing positive
only for alcohol, alcohol and drugs (Table 2), and for drugs without
the presence of alcohol or medicines (time 1: 6.93% [6.07–7.80];
time 2: 4.87% [4.09–5.65]; p < 0.01). The decrease in the
prevalence of drugs was due to the less frequent presence of
cannabis, while prevalence of the other categories of illegal drugs
showed no change (Table 2).
Discussion
The results show that the presence of alcohol, drugs, and
medicines continues to be frequent among tested Spanish drivers.
However, data from 2013 clearly show a decrease in the prevalence
of cases that tested positive for alcohol and/or drugs on the
roadside screening test (a decrease of 4.27 points, or a decrease of
26.13% with respect to 2008–9) as well as in the laboratory test
Table 1
Analyzed substances and cut-off concentrations in native oral ﬂuid determining
positivity according to DRUID criteria (Go´mez-Talego´n et al., 2012).
Substance Oral ﬂuid analytical
cut-off (ng/ml)
Breath (mg/L)
Ethanol – 0.05
6-Acetilmorphine 16.0
Alprazolam 3.5
Amphetamine 360.0
Benzoilecgonine 95.0
Clonazepam 1.7
Cocaine 170.0
Codeine 94.0
Diazepam 5.0
Flunitrazepam 1.0
Lorazepam 1.1
MDA 220.0
MDEA 270.0
MDMA 270.0
Metadone 22.0
Metamphetamine 410.0
Morphine 95.0
Nordiazepam 1.1
Oxazepam 13.0
THC 27.0
Zolpidem 10.0
Zopiclone 25.0
Tramadol 480.0
7-Amino-clonazepam 3.1
7-Amino-ﬂunitrazepam 1.0
Table 2
Results of the screening tests, conﬁrmation of the presence of drugs in oral ﬂuid, and breath alcohol concentration (roadside surveys 2008–9 and 2013).
Roadside survey 2008–9 (n = 3302) Roadside survey 2013 (n = 2932) Test z; p
n % [95% CI] n % [95% CI]
Screening
Negative 2763 83.66 [82.40–84.92] 2578 87.90 [86.72–89.08] 4.744; p < 0.0001
Total positive for alcohol or drug screening 539 16.34 [15.08–17.60] 354 12.07 [10.92–13.28] 4.744; p < 0.0001
+alcohol/drug screening 151 4.58 [3.86–5.29] 97 3.30 [2.66–3.95] 2.485; p < 0.05
alcohol/+drug screening 321 9.73 [8.72–10.74] 233 7.96 [6.98–8.94] 2.413; p < 0.05
+alcohol/+drug screening 67 2.03 [1.55–2.51] 24 0.81 [0.48–1.13] 3.872; p < 0.0001
Results of conﬁrmatory analyses
No substance 2838 85.95 [84.71–87.09] 2658 90.65 [89.66–91.76] 5.702; p < 0.0001
Substance 464 14.05 [12.91–15.29] 274 9.34 [8.24–10.34] 5.702; p < 0.0001
Cannabis (THC) 174 5.28 [4.51–6.04] 92 3.13 [2.50–3.76] 4.094; p < 0.0001
Cocaine 42 1.28 [0.90–1.67] 26 0.87 [0.54–1.21] 1.339; p > 0.05
Amphetamines 2 0.06 [0.00–0.15] 4 0.12 [0.00–0.25] 0.555; p > 0.05
Opiates 5 0.14 [0.01–0.27] 1 0.03 [0.00–0.09] 1.082; p > 0.05
Alcohol > 0.05 162 4.92 [4.18–5.66] 100 3.41 [2.27–4.07] 2.874; p < 0.05
Benzodiazepines 5 0.17 [0.03–0.30] 3 0.09 [0.00–0.20] 0.186; p > 0.05
Multiple drugs 18 0.55 [0.30–0.81] 26 0.90 [0.55–1.24] 1.457; p > 0.05
Alcohol + drugs 56 1.69 [1.25–2.13] 22 0.72 [0.42–1.04] 3.238; p < 0.05
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conﬁrmation (a decrease of 4.71 points, or a decrease of 33.52%
with respect to 2008–9). Even with these favourable results, the
prevalence of cases of drivers under the inﬂuence of alcohol and
drugs is high, and highlights the need for continued intervention in
this area.
From a practical point of view, the results of the screening tests
are decisive when it comes to police procedure. In some countries,
including Spain, when there is a case in which the alcohol
screening has tested positive, there is usually no further drug
testing. One can observe that in the 2008–9 and 2013 studies, the
cases testing positive for alcohol are those that show a breath
alcohol concentration of 0.05 mg/L or more. Nevertheless, the legal
limit in Spain is 0.25 mg/L (0.15 mg/L in novel drivers). The
2013 data show a reduction in cases testing positive for alcohol,
and in cases positive for alcohol and drugs.
The medicinal drugs analyzed were benzodiazepines, some
hypnotic drugs, and some opioids. As a consequence, the
information obtained in this study is limited to those speciﬁc
pharmaceutical groups and only represents part of the problem of
drivers under the inﬂuence of medicines. Benzodiazepines can be
used in the treatment of mental disorders or can be used illicitly
without a prescription. From a road safety perspective, these are
two different problems. The presence of pharmaceuticals was
detected in 24 drivers in 2008–9 and in eight drivers in 2013. Spain
has introduced a pictogram for medicinal drugs, which informs the
driver about a possible reduction in ability to drive safely when
using those medicines (Fierro, Go´mez-Talego´n, & Alvarez, 2013).
This pictogram is printed on the packaging of benzodiazepines,
hypnotic drugs and opioids. In the context of the European DRUID
project, medicines were categorized into four groups (Ravera et al.,
2012). While illicit drugs are non-regulated substances, medicines
are prescribed by physicians and dispensed by pharmacists with
the possibility of receiving appropriate information regarding
ability to drive. Finding a case testing positive to medication can
raise issues for both the police and for government bodies. As a
current policy, the Spanish government has decided not to include
benzodiazepines in road drug testing.
This study has a number of limitations. Firstly, while the same
design and selection criteria were used for both surveys, at time
1 the testing was carried out over an 11 month period, and at time
2, at two points in time, in May and November. National bank –
holidays were taken into account at time 1 but not at time 2. The
rationale for this was that analysis at time 1 revealed that bank
holidays and month of year had no effect (p > 0.05) on the
prevalence of positive cases. However, the different design at time
1 and 2 may have had an impact on the ﬁgures observed. Secondly,
at both times the same testing criteria, cut-offs and conﬁrmation
processes were used. Saliva was collected with StatSureTM in time
1 and QuantisalTM in time 2 as the StatSureTM device had
disappeared from the market by time 2 and the QuantisalTM
device the best substitute. Although a lower recovery for the THC
from the QuantisalTM device than from the StatSureTM device was
observed (Langel et al., 2008), other studies have also found good
recovery for THC from the QuantisalTM device (Quintela et al.,
2006; Moore et al., 2006). In our case, all oral ﬂuid samples (for
time 1 and 2) were analyzed in the same forensic toxicology service
laboratory at the University of Santiago de Compostela and they
found the highest recovery for THC from the QuantisalTM device
(Quintela et al., 2006). A decrease in the prevalence of drugs was
observed, even when taking into account that the amount of drug
recovered from the QuantisalTM device was probably higher than
the StatSureTM, especially for the THC. Thirdly, changes observed
between time 1 and 2 could be related to changes in the prevalence
of drug use among the population. Data from the Spanish national
drug use surveys on the adult population (15–65 years old) are
collated every two years, and there are data from 1995 to 2013
(PNSD, 2015). Figures on cannabis, do not show a clear trend
between 2007 and 2013: lifetime use, 2007, 27.3%; 2009, 32.1%;
2011, 27.4%; 2013, 30.4%; past-month use 2007, 7.2%; 2009, 7.6%,
2011, 7.0%; 2013, 6.6%; daily use in the past month 2007, 1.7%,
2009, 2.0%, 2011, 1.7%; 2013, 1.9%. Regarding cocaine and
stimulant drugs, there may be a decreasing trend in use over
these years.
Although this study’s design does not allow us to determine all
the factors behind this decrease, the routine implementation of
roadside drug tests may have been a contributing factor. As
previously noted (DRUID, 2009, p. 11), ‘‘the experience of random
testing in trafﬁc in Victoria (Australia) showed that on-site
screening devices have a good performance as a deterrent, leading
to a marked decrease in the prevalence of THC, MDMA and
methamphetamine, the three drugs which are covered in the states
legislation’’. However, the deterrence effect depends on the
frequency of testing as well as the context and may vary
signiﬁcantly with time (Watson & Freeman, 2007). Because of
this, the deterrence effects of random drug testing and the
legislative framework must be evaluated as well as their usefulness
in promoting road safety.
Cannabis dependence and frequency of use have shown
signiﬁcant associations with DUI of cannabis (Jones et al., 2006).
A key factor for deterring DUI is to convince drug-using drivers that
their risk of detection is high (Jones et al., 2006). However, the
severity of punishment does not produce a reduction in DUI of
cannabis. A recent study in Victoria (Australia) suggested that
interventions which address the risk associated with DUI may be
beneﬁcial, particularly those that emphasise the risk of motor
vehicle crashes. Moreover, in this study, cannabis was noted as
special case of intervention due to cannabis users’ reluctance to
change (Matthews, Bruno, Dietze, Butler, & Burns, 2014).
In 2010, legislative measures were introduced which estab-
lished the validity of oral ﬂuid (saliva) as biological evidence for
testing and made the testing mandatory along with the consequent
conﬁrmatory analysis if the screening test were to be positive (Ley
Orga´nica 5/2010). In 2014, a new regulation (Ley 6/2014) has been
introduced which, among other things, increased the ﬁne to
1000 Euro (and a loss of 6 penalty points) for driving under the
inﬂuence of drugs.
In conclusion, this study shows a decrease in the prevalence of
cases testing positive for substances among Spanish drivers.
Despite the marked decrease, detection of alcohol, drugs, and
medicines among Spanish drivers remain common. Preventing
driving under the inﬂuence of substances is a priority for road
safety, particularly in Spain where new legislation (2014) was
introduced to increase the ﬁnes for driving under the inﬂuence. The
political priority given to drug driving in recent years has resulted
in the extension of on-road drug testing. The data from the DRUID
project shows that an extremely increased risk (relative risk 20–
200) was observed among drivers with alcohol in blood 1.2 g/l
and among those with alcohol in combination with drugs; we have
observed a sensible decrease in alcohol + drugs between 2008–9
(1.69%) and 2013 (0.72%). The implementation of these measures
in Spain has helped make driving under the inﬂuence of drugs less
frequent.
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